Results 31 to 40 of about 98,684 (161)

Antifibrotic therapy for fibrotic lung disease beyond idiopathic pulmonary fibrosis

European Respiratory Review, 2019
Two antifibrotic medications (nintedanib and pirfenidone) were recommended (conditionally) for the treatment of patients with idiopathic pulmonary fibrosis (IPF) in the 2015 IPF evidence-based guidelines.
Bridget F. Collins, Ganesh Raghu
doaj   +1 more source

The incidence of malignancies in asbestosis with chrysotile exposure: a large Chinese prospective cohort study

Frontiers in Oncology, 2023
BackgroundAsbestos exposure is closely related to the occurrence and development of various malignancies. This prospective cohort study aimed to evaluate the incidence rate and potential risk factors in a cohort of asbestosis patients in China.MethodsThe
Jingwei Wang, Xiaoyun Huang, Xiaoyun Huang, Ruimin Ma, Qian Zhang, Na Wu, Xuqin Du, Qiao Ye   +7 more
doaj   +1 more source

Imaging diagnosis-computed tomography of traction bronchiectasis secondary to pulmonary fibrosis in a Patterdale Terrier [PDF]

, 2016
An 8-year-old, Patterdale terrier was referred for evaluation of tachypnoea, exercise intolerance, and weight loss. Computed tomographic images showed pneumomediastinum, diffuse pulmonary ground glass opacity, and marked dilatation of peripheral bronchi,
Fitzgerald, E, Lamb, C R, Priestnall, S L   +2 more
core   +2 more sources

Prognosis and Follow-Up of Idiopathic Pulmonary Fibrosis

Medical Sciences, 2018
Idiopathic pulmonary fibrosis (IPF), a devastating progressive interstitial lung disease (ILD) with no known cause, is the most common and deadly of the idiopathic interstitial pneumonias.
Estrella Fernández Fabrellas, Ricardo Peris Sánchez, Cristina Sabater Abad, Gustavo Juan Samper   +3 more
doaj   +1 more source

Small airway dysfunction in pneumoconiosis: a cross-sectional study

BMC Pulmonary Medicine, 2022
Background Although several histological studies have documented airway inflammation and remodelling in the small airways of dust-exposed workers, little is known regarding the prevalence and risk factors of small airway dysfunction (SAD) in ...
Yali Fan, Ruimin Ma, Xuqin Du, Dandan Chai, Shuangli Yang, Qiao Ye   +5 more
doaj   +1 more source

Is the internet a sufficient source of information on sarcoidosis?

Frontiers in Medicine, 2023
IntroductionMany patients use the internet as a source of health information. Sarcoidosis is a complex disease, and internet resources have not yet been analyzed for reliability and content on sarcoidosis.AimsOur study aimed to investigate the content ...
Katharina Buschulte, Philipp Höger, Claudia Ganter, Marlies Wijsenbeek, Nicolas Kahn, Katharina Kriegsmann, Finn M. Wilkens, Jolene H. Fisher, Christopher J. Ryerson, Felix J. F. Herth, Michael Kreuter, Michael Kreuter   +11 more
doaj   +1 more source

Assessment of pulmonary edema: principles and practice [PDF]

, 2018
Pulmonary edema increasingly is recognized as a perioperative complication affecting outcome. Several risk factors have been identified, including those of cardiogenic origin, such as heart failure or excessive fluid administration, and those related to ...
Assaad, Sherif, Friedman, Malcolm B., Kratzert, Wolf B., Perrino, Albert, Shelley, Benjamin   +4 more
core   +1 more source

Activation of Downstream mTORC1 Target Ribosomal Protein S6 Kinase (S6K) Can Be Found in a Subgroup of Dutch Patients with Granulomatous Pulmonary Disease

Cells, 2021
Mechanistic target of rapamycin complex 1 (mTORC1) has been linked to different diseases. The mTORC1 signaling pathway is suggested to play a role in the granuloma formation of sarcoidosis.
Raisa Kraaijvanger, Kees Seldenrijk, Els Beijer, Jan Damen, Jayne Louise Wilson, Thomas Weichhart, Jan C. Grutters, Marcel Veltkamp   +7 more
doaj   +1 more source

Endothelial to mesenchymal transition (EndoMT) in the pathogenesis of Systemic Sclerosis-associated pulmonary fibrosis and pulmonary arterial hypertension. Myth or reality? [PDF]

, 2016
Systemic Sclerosis (SSc) is a systemic autoimmune disease characterized by progressive fibrosis of skin and multiple internal organs and severe functional and structural microvascular alterations.
Jimenez, Sergio A., Piera-Velazquez, Sonsoles   +1 more
core   +2 more sources

The therapy of idiopathic pulmonary fibrosis: what is next?

European Respiratory Review, 2019
Idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, fibrosing interstitial lung disease, characterised by progressive scarring of the lung and associated with a high burden of disease and early death.
Vivien Somogyi, Nazia Chaudhuri, Sebastiano Emanuele Torrisi, Nicolas Kahn, Veronika Müller, Michael Kreuter   +5 more
doaj   +1 more source